Certara appoints Nathan Teuscher to lead Phoenix Software Division
Thursday, July 21, 2016
Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has announced the appointment of Nathan Teuscher, Ph.D., to vice president of pharmacometric solutions. In his new role, Dr. Teuscher will lead the company’s Phoenix software division. He previously served as Certara’s vice president of scientific training.
Dr. Teuscher is the former founder and president of clinical pharmacology consultancy PK/PD Associates, which Certara acquired in Aug. 2015.
“A customer-centric professional, Dr. Teuscher is both a renowned modeler and an accomplished educator in the field of pharmacometrics,” said Certara Chief Executive Officer Edmundo Muniz, M.D., Ph.D. “This appointment will facilitate the Phoenix software platform’s evolution and also support our goal of further engaging the industry about the benefits and usage of modeling and simulation in drug development.”
Dr. Teuscher has held leadership roles in the pharmaceutical industry as a scientist, consultant, and teacher in pharmacokinetics, clinical pharmacology and pharmacometrics. Early in his career, Dr. Teuscher was recognized as a Computerworld Smithsonian Laureate for his work on developing a pioneering web-application to teach pharmacokinetics to pharmacy students at the University of Michigan. Since that time, he has developed many educational tools, including mobile and web applications for pharmacometric analyses.
Phoenix is the pharmaceutical industry’s premier software platform for managing, analyzing and reporting pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic data. It is used to analyze the safety and efficacy of drugs under development by pharmaceutical, veterinary and academic researchers, and the FDA and other global regulatory agencies. Phoenix WinNonlin, considered the industry’s ‘gold standard’ for non-compartmental analysis, is used by 6,000 researchers in 50 countries.